Hydroxyquinoline Tyrosinase Inhibitors Using Copper Chelation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional tyrosinase inhibitors for treating hyperpigmentation disorders, such as hydroquinone and kojic acid, face issues of toxicity and efficacy concerns, necessitating the development of safer and more effective alternatives.

Innovation Solution

Hydroxyquinolines, a class of antibiotics, are repurposed as tyrosinase inhibitors that act through a unique mechanism of metal chelation and extraction, inhibiting melanin production by binding to the enzyme's copper ions in the active site.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional tyrosinase inhibitors like hydroquinone are used to treat hyperpigmentation, then depigmenting efficacy is improved, but toxicity increases

Engineering Contradiction:

Improvedepigmenting efficacyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the toxic oxidation product (benzoquinone) pathway by using hydroxyquinoline compounds that inhibit tyrosinase through metal chelation rather than oxidation. This removes the harmful byproduct generation while preserving the depigmenting effect, directly resolving the contradiction between efficacy and toxicity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces hydroxyquinoline compounds as intermediary substances that bind to copper ions in the tyrosinase active site through chelation. This intermediary mechanism blocks substrate access and inhibits enzyme activity without undergoing oxidation itself, thereby preventing toxic benzoquinone formation while maintaining effective depigmentation.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If hydroquinone is used as a tyrosinase inhibitor, then melanin production is inhibited, but mutagenic and carcinogenic effects occur

Engineering Contradiction:

Improvemelanin inhibitionVSAvoidmutagenic and carcinogenic effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful oxidation pathway of hydroquinone into a beneficial non-oxidative mechanism. By designing hydroxyquinoline compounds that inhibit tyrosinase through copper chelation rather than oxidation, the invention eliminates mutagenic and carcinogenic effects while preserving melanin inhibition efficacy.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Hydroxyquinoline compounds serve as intermediary agents that bind to copper ions in the tyrosinase active site, blocking enzyme function without undergoing oxidation. This intermediary chelation mechanism prevents the formation of mutagenic benzoquinone while effectively inhibiting melanin production.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If rhododendrol is used for skin lightening, then depigmenting effect is achieved, but cytotoxicity to melanocytes occurs

Engineering Contradiction:

Improvedepigmenting effectVSAvoidcytotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses hydroxyquinoline compounds as intermediary substances that selectively bind to copper ions in tyrosinase through chelation. This mechanism inhibits melanin production without causing cytotoxicity to melanocytes, resolving the contradiction between depigmenting effect and cellular safety.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12357552B2Hydroxyquinoline compounds and methods of use as pigment modifying agents

Publication Date: 2025.07.15 GERMANAS JURIS

AI summary

Embodiments disclosed provide pharmaceutical formulations for tyrosinase inhibitors, as well as methods for dermatological treatment of hyperpigmentation disorders. The pharmaceutical formulations comprise tyrosinase inhibitors, each containing a structural core of 8-hydroxyquinoline, and are applied in a suitable carrier as topical treatments for hyperpigmentation. In some embodiments at least one additional dermatologically active compound is present in the pharmaceutical formulation.